Shanghai Medicilon Inc.

  On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"!  Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor! The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields.  The list represents the highest level of  China's pharmaceutical CRO/CDMO industry .

  On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries. Shanghai Medicilon Inc. (Medicilon) was listed in the "Top 20 CXO (including CDMO) Enterprises in China".  This is the 4th consecutive year that Medicilon has won this honor. It is understood that the "Top 100 List of China's Pharmaceutical Industry" has become one of the most concerned and authoritative pharmaceutical rankings in China for more than 10 consecutive years. Reference: Medicilon's CDMO Service Platform Top 10 Global CDMO Enterprises Medicilon was Awarded The "Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise" Medicilon was listed in the "Top 20 CXO (including CDMO) Enterprises in China", which is the inevitable result of Medicilon's 18 years of rooting in new...

  ❖  Contract Research Organization CRO Contract Research Organization, referred to as CRO, mainly provides drug discovery, preclinical research, clinical trials and other new drug R&D contract research services for multinational pharmaceutical companies and pharmaceutical companies. At present, biomedical R&D outsourcing has gradually become an indispensable link in the pharmaceutical industry chain and plays an important role in the industrial structure. ❖      Medicilon’s Preclinical Research Services Medicilon is a Preclinical Research Outsourcing (CRO) company. With our more than 10 years experience on preclinical research services, we dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to sel...

  Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research. After this appointment, Dr. Zhang will further promote Medicilon to enter the CDMO field, help Medicilon to establish a large-scale production base in line with GMP standards through strategic cooperation, self-construction or merger and acquisition, further improve the crystal research service platform, strengthen the construction of technical platform in the field of small nucleic acid drugs and polypeptide drug preparations, and help Medicilon achieve "CRO+CDMO" two-wheel drive. At the same time, Dr. Zhang will also further promote the business development of Medicilon and help Medicilon to research and develop new drugs. Dr. Rui Zhang, Ph.D., University of Victoria, Postdoc at the School of Pharmacy, University of Manitoba, has been deeply involved in the field of drug research and development for 15 years. He...

  The MAH system has brought unprecedented opportunities and challenges to the Chinese pharmaceutical industry. Combined with the current development of the world's biopharmaceutical industry, the article will take you to understand the development pattern and current situation of the pharmaceutical CDMO industry, and understand the background of the CDMO industry development driven by policies and dividends. 01      Introduction to CDMO Industry Services The  CDMO (Contract Development Manufacture Organization) business model  includes the entire supply chain system from preclinical research, clinical trials to commercial production, including R&D, procurement, and production. It provides innovative process R&D and large-scale production services for pharmaceutical companies. Technology output with higher added value replaces pure capacity output. 02     Global CDMO Market Status, Scale 01   The global CDMO market size is nearly...

  In recent years, the global   CDMO  industry has maintained steady growth. In terms of revenue, Switzerland's   Lonza  ranks first, with sales of 5.4 billion Swiss francs in 2021, a year-on-year increase of 20%. Followed by are WuXi AppTec and WuXi Biologics, the total revenue was US$5.214 billion, a year-on-year increase of 49.83%, with nearly 45,000 total employees. There are 9 companies with revenue of more than 1 billion US dollars. Two companies wihch from China and South Korea are on the list. The rest are European and American companies, and there is only one company  Catalent  in the United States. From the perspective of revenue growth, WuXi has grown by 50% year-on-year last year, far exceeding other companies. Catalent's  revenue in last year was $3.998 billion, a year-on-year increase of 29%, ranking third. In March 2013, Catalent established the 8th clinical supply center in the world and the 1st clinical supply center in China, and...